Source: Annual Congress 2009 - Treatment of lung cancer
Disease area: Thoracic oncology

Abstract

Introduction: Erlotinib is a inhibitor of the receptor for epidermal growth factor (EGFR) indicated in treatment of non-small cell lung cancer (NSCLC), advanced disease. Factors predictive of good response to erlotinib are asian origin of patients, histological type of adenocarcinoma, female gender, absence of smoking and EGFR mutation. Methods: A prospective study of 38 patients with NSCLC, advanced disease, performance status (PS) ≤3 and progression after 1st or 2nd line chemotherapy, treated with erlotinib 150mg/day. Results: By 31 July 2008 underwent chemotherapy with erlotinib 38 patients (19 women and 19 men), median age of 61 years. Twelve patients were smokers, 7 ex-smokers and 19 non-smokers. The predominant histological type was adenocarcinoma (66%), followed by squamous cell carcinoma (21%) and unspecified NSCLC (13%). The PS was 1 in 63.2%. The study of EGFR mutation was performed in 24 patients and was positive in 6 patients, negative in 14 cases, inconclusive in 1 case and is ongoing in 3 patients. The median duration of therapy with erlotinib was 2.5 months (mean 5.5 months). The overall survival was 55.3 months after diagnosis. The survival after initiation of erlotinib was 16.2 months, higher in non-smokers (24.8 months) and 10.8 months in smokers and former smokers (p = 0.483). This study did not reach statistical significance given the small number of patients, although showing a trend towards increased survival in non-smokers treated with erlotinib.
Conclusion: The condition of non smoker is associated with better response to therapy with erlotinib and time to progression, however further studies with larger number of patients and signaling EGFR mutation are required.

Rating:

Share or cite this content

Citations should be made in the following way:
J. Gomes, A. Antunes, C. Lima, A. Barroso, D. Ferreira, S. Neves, S. Conde, B. Parente (Vila Nova de Gaia, Portugal). Tobacco exposure and survival in non small cell lung cancer patients treated with erlotinib. Eur Respir J 2009; 34: Suppl. 53, 2655

Member's Comments

No comment yet.

Related content which might interest you: Impact of radiotherapy on survival rates in chemotherapy treated non small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 C-erbB-3 expression in non small cell lung cancer (NSCLC) patients treated by erlotinib Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Impact of radiotherapy on survival rates in chemotherapy treated small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Survival of patients with relapsing small cell lung cancer (SCLC) after new line chemotherapy administration Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Combination of erlotinib and bevacizumab in non small cell lung cancer patients Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Gefitinib in the non small cell lung cancer treatment: contribution to prolongation and quality of survival Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Predictors of radiation-induced lung toxicity in patients with locally advanced non small cell lung cancer (NSCLC): a retrospective analysis Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 Long-term survival of the patients with advanced non small cell lung carcinomas after induction chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Cancer recurrence in surgically treated non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 755s Year: 2006 The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004 Early concurrent chemoradiotherapy for limited small cell lung cancer (LSCLC). Analysis of toxicity and survival of 30 consecutive patients Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Small cell lung cancer patients and their responses to treatment Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004 Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011 Second-line treatment patients at relapse of disseminated small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001 Endoscopical laser treatment in combined therapy non small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment Source: Eur Respir J 2002; 20: Suppl. 38, 400s Year: 2002